113
Participants
Start Date
February 18, 2019
Primary Completion Date
May 30, 2022
Study Completion Date
March 8, 2026
Allogenic BM-MSCs Injection
Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
Sham Procedure
sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
Clínica Universidad de Navarra, Pamplona
UH Montpellier, Montpellier
Hospital Sagrado Corazón Valladolid, Valladolid
CHU Saint Antoine, Paris
CHU de Nantes, Nantes
APHP Cochin, Paris
BG Klinikum Bergmannstrost, Halle
Campus Bio-Medico University of Rome, Roma
Institut de Teràpia Regenerativa Tissular, Barcelona
Interdisziplinäres Zentrum Klinische Studien (IZKS)
UNKNOWN
European Clinical Research Infrastructure Network
OTHER
Département de l'information médicale, CHU de Montpellier
UNKNOWN
Centre National de la Recherche Scientifique, France
OTHER
Université Montpellier
OTHER
Univercell-Biosolutions S.A.S
UNKNOWN
National University of Ireland, Galway, Ireland
OTHER
University of Valladolid
OTHER
Citospin
INDUSTRY
Rennes University Hospital
OTHER
APHP
OTHER
Campus Bio-Medico University
OTHER
BG Klinikum Bergmannstrost, Halle, Germany
UNKNOWN
Nantes University Hospital
OTHER
Institut de Terapia Regenerativa Tissular
OTHER
University of Navarra
OTHER
University Hospital, Montpellier
OTHER